A Phase 3 interventional study of docetaxel and docetaxel in Carcinoma, Non-Small-Cell Lung, sponsored by Boehringer Ingelheim. Terminated at 13 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-13.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 2 under way, none of them phase 3. nintedanib · Carcinoma, Non-Small-Cell Lung.
Among the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung, this one is the 12th largest by enrollment, is one of 3 that started in 2014, is one of 3 in phase 3, and was the 11th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →1 of the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung is open now, in 1 country. Recruiting first, the newest first:
China Medical University Hospital · Sites in Taiwan
Ages 20–70
By country, each count listing its studies:
nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 7 · Phase 3 3
First in 2005; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 16 across the 19 interventional studies. Of the 16 that completed or were terminated, 11 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 19 have an industry lead sponsor. The 8 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim: 3 open now, 5 under way, 1 of them phase 3. Of 60 finished, 53 (88%) have results posted.
Among the 68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim, this one is the 43rd largest by enrollment of the 49 interventional ones that give a count, is one of 8 that started in 2014, is one of 14 in phase 3, and was the 38th registered.
Boehringer Ingelheim’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 68 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The present trial will investigate the efficacy and safety of nintedanib in combination with docetaxel as compared to placebo in combination with docetaxel in patients with stage IIIB/IV or recurrent NSCLC of adenocarcinoma histology after failure of first-line platinum-based chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients to receive backbone chemotherapy and placebo
Drug: docetaxel · Drug: placebo
patients to receive backbone chemotherapy and nintedanib
Drug: docetaxel · Drug: nintedanib
intravenous chemotherapy drug
intravenous chemotherapy drug
oral placebo
oral experimental therapy
Disease Control According to Response Evaluation Criteria in Solid Tumours (RECIST), Version 1.1
This outcome measure presents the number of patients with disease control according to RECIST, version 1.1, defined as number of patients with Complete response, partial response or stable disease.
Time frame: Up to 6 months.
| Milestone | Placebo | Nintedanib |
|---|---|---|
| Started | 6 | 6 |
| Completed | 0 | 0 |
| Not completed | 6 | 6 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Lack of efficacy | 4 | 3 |
| Withdrew: Withdrawal by subject | 1 | 2 |
This outcome measure presents the number of patients with disease control according to RECIST, version 1.1, defined as number of patients with Complete response, partial response or stable disease.
| Percentage of participants | Placebo | Nintedanib |
|---|---|---|
| Yes | 66.7 | 50.0 |
| No | 33.3 | 50.0 |
Collected over From first drug administration until 28 days after last drug administration, up to 7 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 3/6 (50%) | 5/6 (83.3%) |
| Nintedanib | — | 3/6 (50%) | 6/6 (100%) |
| Event | Placebo | Nintedanib |
|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/6 | 0/6 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/6 | 1/6 |
| Atrial fibrillationCardiac disorders | 1/6 | 0/6 |
| Cardio-respiratory arrestCardiac disorders | 1/6 | 0/6 |
| TachycardiaCardiac disorders | 1/6 | 0/6 |
| Clostridium difficile infectionInfections and infestations | 1/6 | 0/6 |
| PneumoniaInfections and infestations | 1/6 | 1/6 |
| SepsisInfections and infestations | 0/6 | 1/6 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/6 | 0/6 |
| Lactic acidosisMetabolism and nutrition disorders | 0/6 | 1/6 |
| Event | Placebo | Nintedanib |
|---|---|---|
| NauseaGastrointestinal disorders | 1/6 | 5/6 |
| VomitingGastrointestinal disorders | 0/6 | 5/6 |
| DiarrhoeaGastrointestinal disorders | 3/6 | 4/6 |
| FatigueGeneral disorders | 4/6 | 3/6 |
| Decreased appetiteMetabolism and nutrition disorders | 2/6 | 4/6 |
| NeutropeniaBlood and lymphatic system disorders | 2/6 | 3/6 |
| Abdominal painGastrointestinal disorders | 3/6 | 2/6 |
| Neuropathy peripheralNervous system disorders | 1/6 | 3/6 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/6 | 2/6 |
| AlopeciaSkin and subcutaneous tissue disorders | 3/6 | 2/6 |
Randomised Set: The randomised set included all randomised patients.
| Age, Continuous(Years) | Placebo | Nintedanib | Total |
|---|---|---|---|
| Mean | 59.7 ± 12.2 | 63.3 ± 8.3 | 61.5 ± 10.1 |
| Sex: Female, Male(Participants) | Placebo | Nintedanib | Total |
|---|---|---|---|
| Female | 1 | 2 | 3 |
| Male | 5 | 4 | 9 |
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency
Ran from Oct 2014 to primary completion in Dec 2015, 14 months.
Results were first posted in Feb 2017, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nintedanib
Carcinoma, Non-Small-Cell Lung →